scispace - formally typeset
Journal ArticleDOI

ERBB receptors and cancer: the complexity of targeted inhibitors.

TLDR
This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.
Abstract
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.

read more

Citations
More filters
Journal ArticleDOI

EGFR and HER2 signaling in breast cancer brain metastasis.

TL;DR: This review will first provide an overview of the HER2 and EGFR signaling pathways, then the roles that EGFR and HER2 play in breast cancer metastasis to the brain will be discussed, and the preclinical and clinical effects of EGFR- and Her2-targeted therapies on breast Cancer metastasis are summarized.
Journal ArticleDOI

HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes.

TL;DR: Data indicate an important role of ErbB2 regulation by HPV16 E6 in oncogenic transformation of human cervical keratinocytes and shows that tumor formation of ErBB2-shRNA introduced SiHa cells were almost abolished.
Journal ArticleDOI

The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.

TL;DR: The role of SLK in chemotaxis downstream of the tyrosine kinase receptor, HER2/ErbB2/Neu, which is frequently overexpressed in human breast cancers, is investigated and an interaction between Neu and SLK signaling in the regulation of cancer cell motility is defined.
Journal ArticleDOI

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.

TL;DR: High-level ERBB2 amplification occurs in a small fraction of lung cancers with a strong propensity to high-grade adenocarcinomas, andeterogeneity of amplification may limit the utility of anti-HER2 therapy in some of these tumors.
Journal ArticleDOI

Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.

TL;DR: It is demonstrated the importance of understanding the influence of the antibody-conjugate on cell trafficking for ultimate optimization of treatment selection by utilizing phage-display technology to generate a novel anti-HER2 mAb that binds an epitope of HER2 distinct from that of trastuzumab.
References
More filters
Journal ArticleDOI

The hallmarks of cancer.

TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Related Papers (5)